Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'STEGER GG' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 44 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Hejna, M; Kostler, WJ; Raderer, M; Steger, GG; Brodowicz, T; Scheithauer, W; Wiltschke, C; Zielinski, CC
      Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial

      EUROPEAN JOURNAL OF CANCER
    2. Locker, GJ; Wenzel, C; Schmidinger, M; Gnant, MFX; Marosi, C; Jakesz, R; Zielinski, CC; Steger, GG
      Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancerpatients

      ANTI-CANCER DRUGS
    3. Schmidinger, M; Budinsky, AC; Wenzel, C; Locker, GJ; Pluschnig, U; Brodowicz, T; Kubista, E; Maca, S; Zabernigg, A; Ilsinger, P; Seewann, L; Hojas, S; Blach, M; Zielinski, CC; Steger, GG
      Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    4. Mader, RM; Schmidt, WM; Sedivy, R; Rizovski, B; Braun, J; Kalipciyan, M; Exner, M; Steger, GG; Mueller, MW
      Reverse transcriptase template switching during reverse transcriptase-polymerase chain reaction: Artificial generation of deletions in ribonucleotidereductase mRNA

      JOURNAL OF LABORATORY AND CLINICAL MEDICINE
    5. Friedl, J; Stift, A; Paolini, P; Roth, E; Steger, GG; Mader, R; Jakesz, R; Gnant, MFX
      Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    6. Brodowicz, T; Kostler, WJ; Moslinger, R; Tomek, S; Vaclavik, I; Herscovici, V; Wiltschke, C; Steger, GG; Wein, W; Seifert, M; Kubista, E; Zielinski, CC
      Single-agent gemcitabine as second- and third-line treatment in metastaticbreast cancer

      BREAST
    7. Brodowicz, T; Wolfram, RM; Kostler, WJ; Tomek, S; Vaclavik, I; Steger, GG; Teleky, B; Fugger, R; Jakesz, R; Zielinski, CC
      Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer

      ANTI-CANCER DRUGS
    8. Brodowicz, T; Koestler, WJ; Tomek, S; Vaclavik, I; Herscovici, V; Wiltschke, C; Steger, GG; Zielinski, CC
      Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer

      ANTI-CANCER DRUGS
    9. Schmidinger, M; Steger, GG; Budinsky, AC; Wenzel, C; Brodowicz, T; Locker, GJ; Kramer, G; Marberger, M; Zielinski, CC
      Vinorelbine and interferon-alpha 2c as second-line therapy in metastatic renal cell carcinoma

      ANTI-CANCER DRUGS
    10. Locker, GJ; Mader, RM; Steiner, B; Wenzl, E; Zielinski, CC; Steger, GG
      Benefit of interferon-alpha(2b) in a patient with unresectable hepatoma and chronic infection with hepatitis C virus

      EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
    11. Schmidinger, M; Steger, GG; Wenzel, C; Locker, GJ; Brodowicz, T; Budinsky, AC; Wiltschke, C; Kramer, G; Marberger, M; Zielinski, CC
      Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    12. Muller, M; Bockenheimer, J; Zellenberg, U; Klein, N; Steger, GG; Eichler, HG; Mader, RM
      Relationship between in vivo drug exposure of the tumor interstitium and inhibition of tumor cell growth in vitro: a study in breast cancer patients

      BREAST CANCER RESEARCH AND TREATMENT
    13. Schmidinger, M; Budinsky, AC; Wenzel, C; Piribauer, M; Brix, R; Kautzky, M; Oder, W; Locker, GJ; Zielinski, CC; Steger, GG
      Glutathione in the prevention of cisplatin induced toxicities - A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer

      WIENER KLINISCHE WOCHENSCHRIFT
    14. Sedivy, R; Wolf, B; Kalipciyan, M; Steger, GG; Karner-Hanusch, J; Mader, RM
      Genetic analysis of multiple synchronous lesions of the colon adenoma-carcinoma sequence

      BRITISH JOURNAL OF CANCER
    15. Locker, GJ; Steger, GG; Gnant, MFX; Steiner, B; Simonitsch, I; Krainer, M; Budinsky, A; Brodowicz, T; Spitzauer, S; Jakesz, R; Zielinski, CC
      Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?

      JOURNAL OF IMMUNOTHERAPY
    16. Wenzel, C; Schmidinger, M; Locker, GJ; Taucher, S; Gnant, M; Jakesz, R; Steger, GG
      Clinical phase II evaluation of the combination therapy with Docetaxel andEpidoxorubicin in the neoadjuvant, cytostatic treatment on patients with primary breast cancer (T1-4, N0-2, M0)

      WIENER KLINISCHE WOCHENSCHRIFT
    17. Locker, GJ; Mader, RM; Rizovski, B; Knapp, S; Domanovits, H; Muellner, M; Hoeller, C; Steger, GG; Sterz, F; Freissmuth, M; Frass, M; Laggner, AN
      Negative chronotropic effects of fentanyl attenuate beneficial effects of dobutamine on oxygen metabolism: Hemodynamic and pharmacokinetic interactions

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    18. Locker, GJ; Kapiotis, S; Veitl, M; Mader, RM; Stoiser, B; Kofler, J; Sieder, AE; Rainer, H; Steger, GG; Mannhalter, C; Wagner, OF
      Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders

      BRITISH JOURNAL OF HAEMATOLOGY
    19. MADER RM; MULLER M; STEGER GG
      RESISTANCE TO 5-FLUOROURACIL

      General pharmacology
    20. Mader, RM; Brunner, M; Rizovski, B; Mensik, C; Steger, GG; Eichler, HG; Muller, M
      Analysis of microdialysates from cancer patients by capillary electrophoresis

      ELECTROPHORESIS
    21. DJAVANMARD MP; KRAMER G; STEGER GG; ZIELINSKI C; MARBERGER M
      MULTICENTER PHASE TRIAL OF OUTPATIENT THERAPY WITH SEQUENTIAL LOW-DOSE INTERFERON-GAMMA-1B AND INTERLEUKIN-2 IN ADVANCED RENAL-CELL CARCINOMA

      The Journal of urology
    22. MULLER M; BRUNNER M; SCHMID R; MADER RM; BOCKENHEIMER J; STEGER GG; STEINER B; EICHLER HG; BLOCHLDAUM B
      INTERSTITIAL METHOTREXATE KINETICS IN PRIMARY BREAST-CANCER LESIONS

      Cancer research
    23. STEGER GG; DJAVANMARD MP; STEINER B; BUDINSKY AC; BRODOWICZ T; BLOCHLDAUM B; HUBER H; MARBERGER M; ZIELINSKI C
      INTERFERON-GAMMA (IFN-G) AND INTERLEUKIN-2 (IL-2) IS A FEASIBLE AND EFFECTIVE OUTPATIENT REGIMEN FOR ADVANCED RENAL-CELL CANCER

      European journal of cancer
    24. STEGER GG; GNANT MF; DJAVANMARD MP; MADER RM; JAKESZ R; PIERCE W; DEKERNION JB; FIGLIN R; BELLDEGRUN A
      THE IN-VITRO EFFECTS OF INTERLEUKIN-12 UPON TUMOR-INFILTRATING LYMPHOCYTES DERIVED FROM RENAL-CELL CARCINOMA

      Journal of cancer research and clinical oncology
    25. BRODOWICZ T; WILTSCHKE C; BUDINSKY AC; KRAINER M; STEGER GG; ZIELINSKI CC
      SOLUBLE HER-2 NEU NEUTRALIZES BIOLOGIC EFFECTS OF ANTI-HER-2/NEU ANTIBODY ON BREAST-CANCER CELLS IN-VITRO/

      International journal of cancer
    26. MULLER M; MADER RM; STEINER B; STEGER GG; JANSEN B; GNANT M; HELBICH T; JAKESZ R; EICHLER HG; BLOCHLDAUM B
      5-FLUOROURACIL KINETICS IN THE INTERSTITIAL TUMOR SPACE - CLINICAL-RESPONSE IN BREAST-CANCER PATIENTS

      Cancer research
    27. MADER RM; SIEDER AE; BRAUN J; RIZOVSKI B; KALIPCIYAN M; MUELLER MW; JAKESZ R; RAINER H; STEGER GG
      TRANSCRIPTION AND ACTIVITY OF 5-FLUOROURACIL CONVERTING ENZYMES IN FLUOROPYRIMIDINE RESISTANCE IN COLON-CANCER IN-VITRO

      Biochemical pharmacology
    28. FINDENIG G; MADER RM; FRITZERSZEKERES M; STEGER GG; JAEGER W; SZEKERES T
      MODULATION OF 5-FLUOROURACIL RESISTANCE IN HUMAN COLON-TUMOR CELL-LINES BY AZIDOTHYMIDINE

      Oncology research
    29. MADER RM; RIZOVSKI B; STEGER GG; WACHTER A; KOTZ R; RAINER H
      EXPOSURE OF ONCOLOGIC NURSES TO METHOTREXATE IN THE TREATMENT OF OSTEOSARCOMA

      Archives of environmental health
    30. MADER RM; ZILG H; SCHLAPPACK O; STEGER GG; BAUR M; GREIFENBERG B; HEBERLE U; DITTRICH C
      PHARMACOKINETICS OF 4'O-TETRAHYDROPYRANYLADRIAMYCIN GIVEN ON A WEEKLYSCHEDULE IN PATIENTS WITH ADVANCED BREAST-CANCER

      Cancer chemotherapy and pharmacology
    31. MADER RM; STEGER GG; RIZOVSKI B; DJAVANMARD MP; SCHEITHAUER W; JAKESZ R; RAINER H
      STEREOSPECIFIC PHARMACOKINETICS OF RAC-5-METHYLTETRAHYDROFOLIC ACID IN PATIENTS WITH ADVANCED COLORECTAL-CANCER

      British journal of clinical pharmacology
    32. LOCKER GJ; SIMONITSCH I; MADER RM; WARLAMIDES E; GNANT MFX; JAKESZ R; RAINER H; STEGER GG
      CUTANEOUS SIDE-EFFECTS IN BREAST-CANCER PATIENTS TREATED WITH CYTOSTATIC POLYCHEMOTHERAPY AND RH GM-CSF - IMMUNE PHENOMENA OR DRUG TOXICITY

      Breast cancer research and treatment
    33. LOCKER GJ; MADER RM; BRAUN J; SIEDER AE; MAROSI C; RAINER H; JAKESZ R; STEGER GG
      NEW MUCIN-LIKE CANCER-ASSOCIATED ANTIGENS (CA-M-26, CA-M-29 AND CA-549) AND A NEW PROLIFERATION MARKER (TPS) IN PATIENTS WITH PRIMARY OR ADVANCED BREAST-CANCER

      Oncology
    34. STEGER GG; KABOO R; DEKERNION JB; FIGLIN R; BELLDEGRUN A
      THE EFFECTS OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ON TUMOR-INFILTRATING LYMPHOCYTES FROM RENAL-CELL CARCINOMA

      British Journal of Cancer
    35. MADER RM; STEGER GG; BRAUN J; RAINER H
      COMPARISON OF AN IMMUNORADIOMETRIC AND AN IMMUNOLUMINOMETRIC ASSAY FOR THE EVALUATION OF THE TUMOR-ASSOCIATED ANTIGENS CA-19-9 AND CA-125

      European journal of clinical chemistry and clinical biochemistry
    36. STEGER GG; DJAVANMARD MP; GNANT MFX; JAKESZ R
      PREOPERATIVE TAXOL INDUCES OBJECTIVE RESPONSES IN PRIMARY BREAST-CANCER NOT RESPONDING TO FEC TREATMENT

      Annals of oncology
    37. PIRCDANOEWINATA H; CHOTT A; ONDERKA E; DRACH J; SCHLOGL E; JAGER U; THALHAMMER F; NOWOTNY H; ARYEE D; STEGER GG; LOCKER G; MICHL I; DJAVANMARD M; SIMONITSCH I; RADASZKIEWICZ T; HANAK H; SCHNEIDER B; HEINZ R; MAROSI C
      KARYOTYPE AND PROGNOSIS IN NON-HODGKIN-LYMPHOMA

      Leukemia
    38. MADER RM; RAINER H; STEGER GG
      BIOCHEMICAL MODULATION OF FLUOROPYRIMIDINES - PRECLINICAL AND CLINICAL-STUDIES

      Onkologie
    39. MADER RM; STEGER GG; RIZOVSKI B; SIEDER AE; LOCKER G; GNANT MFX; JAKESZ R; RAINER H
      PHARMACOKINETICS OF RAC-LEUCOVORIN VS [S]-LEUCOVORIN IN PATIENTS WITHADVANCED GASTROINTESTINAL CANCER

      British journal of clinical pharmacology
    40. STEGER GG; MADER RM; DJAVANMARD MP; GNANT MFX; LOCKER G; MAROSI C; RAINER H; JAKESZ R
      DOUBLE-MODULATION OF 5-FLUOROURACIL BY HIGH-DOSE LEUCOVORIN AND INTERFERON-ALPHA-2B IN ADVANCED COLORECTAL-CANCER - A PHASE-I AND A PHASE-II STUDY OF WEEKLY ADMINISTRATION

      Journal of cancer research and clinical oncology
    41. STEGER GG; PIERCE WC; FIGLIN R; CZERNIN J; KABOO R; DEKERNION JB; OKARMA T; BELLDEGRUN A
      PATTERNS OF CYTOKINE RELEASE OF UNSELECTED AND CD8-CELL CARCINOMA TUMOR-INFILTRATING LYMPHOCYTES (TIL) - EVIDENCE FOR ENHANCED SPECIFIC KILLING OF TUMOR NECROSIS FACTOR-SECRETING IL-6 NONSECRETING TIL IN-VITROAND CORRELATION WITH COMPLETE RESPONSE IN-VIVO( SELECTED RENAL)

      Clinical immunology and immunopathology
    42. MADER RM; STEGER GG; RIZOVSKI B; JAKESZ R; RAINER H
      DIFFERENT STEREOSPECIFIC PROTEIN-BINDING OF TETRAHYDROFOLATES TO HUMAN SERUM-ALBUMIN

      Journal of pharmaceutical sciences
    43. STEGER GG; MADER RM; VOGELSANG H; SCHOFL R; LOCHS H; FERENCI P
      FOLATE ABSORPTION IN CROHNS-DISEASE

      Digestion
    44. STEGER GG; MADER RM; GNANT MFX; MAROSI C; LENZ K; JAKESZ R
      GM-CSF IN THE TREATMENT OF A PATIENT WITH SEVERE METHOTREXATE INTOXICATION

      Journal of internal medicine


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/06/20 alle ore 21:04:31